Emmaus Life Sciences, Inc.
Moat Score — Emmaus Life Sciences, Inc.
Total Moat Score
4 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 1 / 5 | No composition-of-matter or method-of-use patent on Endari; the only protection is time-limited FDA orphan drug exclusivity (through mid-2024 in the U.S.), not durable intellectual property. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Dependent on a single third-party manufacturer and a single raw-material supplier for pharmaceutical-grade L-glutamine; the company posted a $57.9M net loss against only $7.9M of revenue in 2018, indicating a cost disadvantage, not an edge. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Some pricing power as the only FDA-approved SCD-complication therapy at the time, but directly undercut by inexpensive non-prescription L-glutamine supplements and future disease-modifying competitors. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | None; a specialty pharmaceutical sold through standard distributor-to-pharmacy channels with no network dynamics. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Mild prescriber/patient treatment inertia for a chronic disease therapy, but low formal switching costs given no patent lock-in and generic-supplement substitutes. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The orphan SCD market (~100,000 U.S. patients) is small enough to deter mass-market entry, but was already attracting well-funded competitors (Pfizer, Novartis, Global Blood Therapeutics) pursuing alternative mechanisms. |